Long-term follow-up of 168 patients with X-linked agammaglobulinemia reveals increased morbidity and mortality - 05/08/20

Doi : 10.1016/j.jaci.2020.03.001

Vassilios Lougaris, MD ^a,^⁎ , Annarosa Soresina, MD ^b, Manuela Baronio, PhD ^a, Davide Montin, MD ^c, Silvana Martino, MD ^c, Sara Signa, MD ^d, Stefano Volpi, MD ^d, Marco Zecca, MD ^e, Maddalena Marinoni, MD ^f, Lucia Augusta Baselli, MD ^g, Rosa Maria Dellepiane, MD ^g, Maria Carrabba, MD ^h, Giovanna Fabio, MD ^h, Maria Caterina Putti, MD ⁱ, Francesco Cinetto, MD ^j, Claudio Lunardi, MD ^k, Luisa Gazzurelli, PhD ^a, Alessio Benvenuto, MsC ^a, Patrizia Bertolini, MD ^l, Francesca Conti, MD ^m, Rita Consolini, MD ⁿ, Silvia Ricci, MD ^o, Chiara Azzari, MD ^o, Lucia Leonardi, MD ^p, Marzia Duse, MD ^p, Federica Pulvirenti, MD ^q, Cinzia Milito, MD ^q, Isabella Quinti, MD ^q, Caterina Cancrini, MD ^r, Andrea Finocchi, MD ^r, Viviana Moschese, MD ^s, Emilia Cirillo, MD ^t, Ludovica Crescenzi, MD ^u, Giuseppe Spadaro, MD ^u, Carolina Marasco, MD ^v, Angelo Vacca, MD ^v, Fabio Cardinale, MD ^w, Baldassare Martire, MD ^x, Antonino Trizzino, MD ^y, Maria Licciardello, MD ^z, Fausto Cossu, MD ^aa, Gigliola Di Matteo, PhD ^r, Raffaele Badolato, MD ^a, Simona Ferrari, PhD ^bb, Silvia Giliani, PhD ^cc, Andrea Pession, MD ^m, Alberto Ugazio, MD ^dd, Claudio Pignata, MD ^t, Alessandro Plebani, MD ^a,^⁎
^a Pediatrics Clinic and Institute for Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, University of Brescia and ASST-Spedali Civili di Brescia, Brescia, Italy
^b Pediatrics Clinic, ASST- Spedali Civili of Brescia, Brescia, Italy
^c Division of Pediatric Immunology and Rheumatology, Department of Public Health and Pediatrics, Regina Margherita Children Hospital, University of Turin, Turin, Italy
^d Centro Malattie Autoinfiammatorie e Immunodeficienze-Clinica Pediatrica e Reumatologia, IRCCS Giannina Gaslini, Genova, and Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili, Università di Genova, Genoa, Italy
^e Department of Pediatric Hematology of Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
^f Paediatric Department, ASST-Sette Laghi, F. Del Ponte Hospital, Varese, Italy
^g Department of Pediatrics, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
^h Department of Internal Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
ⁱ Department of Women's and Children's Health, Pediatric Hematology-Oncology Unit, University of Padova, Padua, Italy
^j Padua University, Department of Medicine (DIMED), Internal Medicine I and Rare Disease Center for Immunologic, Rheumatologic and Respiratory Diseases, Ca’ Foncello Hospital, Treviso, Italy
^k Department of Medicine, University of Verona, Verona, Italy
^l Paediatric Hematology Oncology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy
^m Unit of Pediatrics, University of Bologna, St. Orsola University Hospital, Bologna, Italy
ⁿ Section of Pediatrics Immunology and Rheumatology, Department of Pediatrics, University of Pisa, Pisa, Italy
^o Department of Pediatric Immunology, Jeffrey Modell Center for Primary Immunodeficiency, Anna Meyer's Hospital, University of Florence, Florence, Italy
^p Pediatrics Department, Umberto I Hospital, Sapienza University, Roma, Italy
^q Department of Molecular Medicine, Sapienza University of Roma, and Unit of Primary Immunodeficiencies in Adults, Department of Infective diseases and Internal Medicine, Policlinico Umberto I, Rome, Italy
^r University Department of Pediatrics, Unit of Immune and Infectious Diseases, Bambino Gesù Children's Hospital, University of Rome Tor Vergata, and the Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
^s Department of Pediatrics, Policlinico Tor Vergata, Tor Vergata University, Rome, Italy
^t Pediatric Section, Department of Translational Medical Science, Federico II University, Naples, Italy
^u Department of Translational Medical Sciences, Allergy and Clinical Immunology Center for Basic and Clinical Immunology Research, University of Naples Federico II, Naples, Italy
^v Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy
^w Department of Pediatrics and Emergency, Pediatric Allergy and Pulmunology Unit, Azienda Ospedaliera-Universitaria Consorziale-Policlinico, Ospedale Pediatrico Giovanni XXIII, Bari, Italy
^x Pediatric Unit, Monsignor Dimiccoli Hospital, Barletta, Italy
^y Department of Pediatric Hematology and Oncology, ARNAS Civico Di Cristina and Benfratelli Hospital, Palermo, Italy
^z Haematology of Oncology Unit, Department of Pediatrics, University of Catania- Catania, Italy
^aa Second Pediatric Clinic, Antonio Cao Hospital, University of Cagliari, Cagliari, Italy
^bb Unit of Medical Genetics, St. Orsola University Hospital, University of Bologna, Bologna, Italy
^cc Department of Molecular and Translational Medicine, A. Nocivelli Institute for Molecular Medicine, University of Brescia, Brescia, Italy
^dd Institute of Child and Adolescent Health, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

^∗Corresponding author: Vassilios Lougaris, MD, Pediatrics Clinic and Institute of Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, University of Brescia and ASST-Spedali Civili of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy.Pediatrics Clinic and Institute of Molecular Medicine A. NocivelliDepartment of Clinical and Experimental SciencesUniversity of Brescia and ASST-Spedali Civili of BresciaPiazzale Spedali Civili 1Brescia25123Italy^∗∗Alessandro Plebani, MD, PhD, Pediatrics Clinic and Institute of Molecular Medicine A. Nocivelli, Department of Clinical and Experimental Sciences, University of Brescia and ASST-Spedali Civili of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy.Pediatrics Clinic and Institute of Molecular Medicine A. NocivelliDepartment of Clinical and Experimental SciencesUniversity of Brescia and ASST-Spedali Civili of BresciaPiazzale Spedali Civili 1Brescia25123Italy

Abstract

Background

X-linked agammaglobulinemia (XLA) is the prototype of primary humoral immunodeficiencies. Long-term follow-up studies regarding disease-related complications and outcome are scarce.

Objective

Our aim was to describe the natural history of XLA.

Methods

A nationwide multicenter study based on the Italian Primary Immunodeficiency Network registry was established in 2000 in Italy. Affected patients were enrolled by documenting centers, and the patients’ laboratory, clinical, and imaging data were recorded on an annual base.

Results

Data on the patients (N = 168) were derived from a cumulative follow-up of 1370 patient-years, with a mean follow-up of 8.35 years per patient. The mean age at diagnosis decreased after establishment of the Italian Primary Immunodeficiency Network registry (84 months before vs 23 months after). Respiratory, skin, and gastrointestinal manifestations were the most frequent clinical symptoms at diagnosis and during long-term follow-up. Regular immunoglobulin replacement treatment reduced the incidence of invasive infections. Affected patients developed chronic lung disease over time (47% after 40 years of follow-up) in the presence of chronic sinusitis (84%). Malignancies were documented in a minority of cases (3.7%). Overall survival for affected patients was significantly reduced when compared with that for the healthy male Italian population, and it further deteriorated in the presence of chronic lung disease.

Conclusions

This is the first detailed long-term follow-up study for patients with XLA, revealing that although immunoglobulin replacement treatment reduces the incidence of invasive infections, it does not appear to influence the development of chronic lung disease. The overall survival of affected patients is reduced. Further studies are warranted to improve patients’ clinical management and increase awareness among physicians.

Le texte complet de cet article est disponible en PDF.

Key words : X-linked agammaglobulinemia, Bruton tyrosine kinase, chronic lung disease

Abbreviations used : BTK, CLD, IPINet, PVP, SCIG, XLA

Plan

Serum immunoglobulin levels at diagnosis

Lymphocyte subsets at presentation

BTK mutation analysis

Clinical features at diagnosis

Clinical features during follow-up

Pathogen isolation

Genotype-phenotype correlation in XLA

Malignancy

Survival

Immunoglobulin replacement treatment

Discussion

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

Export

Vol 146 - N° 2

P. 429-437 - août 2020 Retour au numéro

Article précédent

Plasma protein profiling reflects T_H1-driven immune dysregulation in common variable immunodeficiency
Jonas Hultberg, Jan Ernerudh, Marie Larsson, Åsa Nilsdotter-Augustinsson, Sofia Nyström

| Article suivant

Hormonal contraceptives and onset of asthma in reproductive-age women: Population-based cohort study
Bright I. Nwaru, Rebecca Pillinger, Holly Tibble, Syed A. Shah, Dermot Ryan, Hilary Critchley, David Price, Catherine M. Hawrylowicz, Colin R. Simpson, Ireneous N. Soyiri, Francis Appiagyei, Aziz Sheikh

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Long-term follow-up of 168 patients with X-linked agammaglobulinemia reveals increased morbidity and mortality - 05/08/20

Abstract

Background

Objective

Methods

Results

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL